Ahammune
4 known investors
Ahammune develops small-molecule therapeutics for chronic skin diseases, with a lead program targeting vitiligo by restoring deregulated cellular pathways in the skin. The company focuses on dermatology drug discovery.
4 known investors
Ahammune develops small-molecule therapeutics for chronic skin diseases, with a lead program targeting vitiligo by restoring deregulated cellular pathways in the skin. The company focuses on dermatology drug discovery.